ArticleOncotarget2018

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.

Guanghong Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.